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H ematopoietic stem cell transplantation (HSCT) is a curative treatment for hematological malig-
nancies,  but it is not generally performed for patients 
with active invasive fungal infections because of the 
high treatment-related mortality [1].  However,  because 
persistent invasive fungal infection itself is lethal,  
HSCT must be performed when disturbed normal 
hematopoiesis prompts the infection.
Fusarium is a rare fungus transmitted to immuno-
compromised patients with poor antifungal susceptibil-
ity,  and the lower neutrophil count is directly linked to 
the dismal prognosis of the disseminated disease.  We 
report a case of HSCT for refractory acute myeloid leu-
kemia (AML) with disseminated fusariosis that devel-
oped during chemotherapy and was refractory to anti-
fungal therapy due to cytopenia.
Case Report
A 53-year-old man visited a local physician with 
complaints of abdominal pain and malaise.  He was 
referred to our hospital because his blood test indicated 
pancytopenia with blasts in peripheral blood and ele-
vated levels of C-reactive protein.  Bone marrow exam-
ination revealed that myeloperoxidase-positive myelo-
blasts accounted for 68.2% of the nucleated cells.  The 
chromosomal test was a normal karyotype; thus,  we 
diagnosed his disease as AML not otherwise specified.  
Also,  computed tomography revealed acute appendici-
tis with localized peritonitis,  and a laparoscopic appen-
dectomy was performed on the day of admission.  On 
postoperative day 11,  induction chemotherapy with 
idarubicin and cytarabine was performed,  but there was 
no recovery of normal hematopoiesis.  One month after 
the commencement of induction chemotherapy,  a bone 
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marrow examination revealed non-remission,  with 
27.4% myeloblasts.  Despite salvage chemotherapy with 
mitoxantrone,  etoposide and cytarabine (MEC ther-
apy),  the pancytopenia persisted,  and the patient 
developed a fever exceeding 38°C.
Although blood cultures were negative,  we changed 
the antibiotic from cefmetazole to doripenem for the 
treatment of febrile neutropenia.  However,  there was 
no improvement of the fever,  and systemic palpable 
papules appeared.  We suspected that the papules were 
caused by some sort of infection rather than drug erup-
tion,  and introduced vancomycin and changed the 
antifungal drug from itraconazole (ITCZ) to 5 mg/kg of 
liposomal amphotericin B (L-AMB).  Nevertheless the 
fever persisted,  and myeloblasts reappeared in the 
peripheral blood.  Thus,  a bone marrow examination 
and skin biopsy were performed (Table 1 and Fig. 1).
Because the papules deteriorated even with a high 
dose of L-AMB and the bone marrow examination 
again showed non-remission,  we assumed that the skin 
lesions were leukemic infiltrations rather than infec-
tious,  and did not perform a culture test.  However,  the 
skin specimen had no evidence of malignancy,  but a 
fungal infection was observed instead.  The pathological 
findings revealed the fungi were true hyphae with septa,  
infiltrating and proliferating into the blood vessels.  
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Fig. 1　 A,  B,  papules are shown (black arrow); C,  Grocott stain of the skin biopsy section showing infiltration of the fungi.
Table 1　 Laboratory data on admission and at the time of occurrence of papules
Bone marrow
aspiration
On
admission
At the time of
emerging papules
Peripheral blood 
& coagulation
On
admission
At the time of
emerging papules
Biochemistry
On
admission
At the time of
emerging papules
NCC 16.9 10.6×104/μL White blood cells 1,050 180/μL C-reactive protein 14.45 12.09 mg/dL
Megakaryocyte 13 56/μL Myeloblast 14 1 % Albumin 4.3 3.3 g/dL
Myeloblast 68.2 48.8 % Neutrophils 5.5 0 % AST 25 20 U/L
Promyelocytes 1.8 0 % Lymphocytes 78 94 % ALT 51 19 U/L
Myelocyte 0.2 0.4 % Monocytes 2 1 % LDH 253 161 U/L
Metamyelocyte 0 0 % Eosinophils 0 0 % ALP 147 288 U/L
Neutrophils 0.2 0.6 % Basophils 0 0 % T-Bil 2.2 1 mg/dL
Eosinophils 0 0 % Aty-Lymp 0.5 4 % CK 40 43 U/L
Basophils 0 0 % EBL 5 0 % BUN 11.8 9.3 mg/dL
Monocytes 0.2 0.4 % Red blood cells 379 245×104/μL Cre 0.74 0.89 mg/dL
Lymphocytes 1.2 5.8 % Hemoglobin 12.3 7.5 g/dl UA 4.1 1.7 mg/dL
Plasma cells 0 4.2 % Hematocrit 36.2 21.7 % Na 139 143 mEq/L
EBL 28.2 31.8 % Platelets 4 4.2×104/μL K 3.4 3.5 mEq/L
MPO stain of Ca 8.7 8.5 mg/dL
myeloblast 82 55 % β-D-Glucan 10.8 10.3 pg/mL
Karyotype Normal Normal GM 0.2 0.1
WT1 5.1×103 1.7×103 copy/μg
NCC,  nucleate cell count; EBL,  erythroblast; MPO,  myeloperoxidase; Aty-Lymp,  atypical lymphocytes; AST,  aspartate aminotransaminase; ALT,  alanine amino-
transaminase; LDH,  lactate dehydrogenase; ALP,  alkaline phosphatase; T-Bil,  total bilirubin; CK,  creatine kinase; BUN,  blood urea nitrogen; Cre,  creatinine; UA,  
uric acid; Na,  sodium; K,  potassium; Ca,  calcium; GM,  galactomannan antigen; WT1,  gene of Wilmsʼ tumor-1 (tumor marker of acute myeloid leukemia).
Based on the morphology and an increase of β-D glu-
can to 10.3 pg/mL in 2 weeks,  the pathogen turned out 
to be a filamentous fungus,  but Aspergillus was unlikely 
because the galactomannan antigen remained below the 
cutoff on the same day of the biopsy.  Given the clinical 
course with fever and skin eruptions,  fusariosis was the 
most suspected condition.  Thus,  we re-examined the 
blood and papule culture tests; however,  both were 
negative.  Despite adding voriconazole (VRCZ) with a 
targeted concentration of trough to 2-4 μg/ml,  the fever 
and papules did not improve,  and β-D glucan increased 
to 23.7 pg/ml 6 weeks after initiation of VRCZ.  Con-
sidering that a superinfection other than Fusarium may 
be present,  we added caspofungin (CPFG).  Combination 
therapy with L-AMB and VRCZ and CPFG stopped the 
enlargement of the papules and slightly reduced β-D 
glucan,  but it did not make β-D glucan undetectable,  
and it did not resolve the fever hovering around 38°C or 
the remaining papules.  Although the causative patho-
gen was not yet detected,  we reasoned that the persist-
ing pancytopenia associated with the leukemia hindered 
the healing of the infection regardless of the pathogen,  
and we again conducted a salvage chemotherapy to con-
trol the underlying disease.  However,  the case ended in 
non-remission again and there was no recovery of nor-
mal hematopoiesis.  We decided to perform allogeneic 
HSCT to treat leukemia and to restore normal hemato-
poiesis to overcome the suspected fusariosis.  We 
obtained informed consent from the patient.
HSCT details. The donor was the patient’s elder 
brother,  who was 6 of 8 alleles matched in the host-
versus-graft direction (HVG) and 8 of 8 alleles matched 
in the graft-versus-host direction.  No donor-specific 
antibody was detected.  The donor source was periph-
eral blood with 7.3 × 106/kg of CD34-positive cells to 
achieve quick engraftment.  Blood types were major/
minor incompatible.  As the underlying disease was 
non-remission,  the conditioning regimen was mye-
loablative and consisted of fludarabine 21 mg/m2 from 
day −7 to day −2,  intravenous busulfan 3.2 mg/kg from 
day −5 to day −2,  and melphalan 40 mg/m2 from day −7 
to day −6.  Graft-versus-host disease (GVHD) prophy-
laxis consisted of continuous intravenous tacrolimus 
targeting a concentration of 10-12 ng/ml and short term 
methotrexate with a dose of 10 , 7 , 7,  and 7 mg/m2 on 
days 1 , 3 , 6,  and 11,  respectively.  We substituted tac-
rolimus for cyclosporine,  which also served to prevent 
rejection associated with mismatches in HVG.  Among 
the antifungal drugs,  CPFG was ceased during the 
administration of busulfan due to a high risk of sinusoi-
dal obstruction syndrome (SOS),  and was resumed 
after busulfan administration.
Clinical course after HSCT. After stem cell trans-
fusion,  the patient’s fever temporarily resolved (Fig. 2).  
On day 3,  however,  the patient lapsed into septic shock 
and experienced refractoriness to platelet transfusion,  
an elevation of total bilirubin (T-Bil) to 4.2 mg/dL,  and 
right costal pain.  We suspected SOS based on the mod-
ified Seattle Criteria and added recombinant human 
soluble thrombomodulin (rTM),  but we could not per-
form a liver biopsy because of severe thrombocytope-
nia.  For this reason,  we changed antibiotics and had to 
stop CPFG.  For early engraftment,  we increased gran-
ulocyte-colony-stimulating factor (G-CSF),  which had 
little effect; the pancytopenia was prolonged and the 
remaining papules gradually enlarged again.  The bone 
marrow examination on day 14 was a dry tap,  which 
prompted us to attempt granulocyte transfusion; how-
ever,  we did not have sufficient time to obtain the 
approval of the ethical board.  On the same day,  
Fusarium was finally detected in a blood culture that 
had been collected on day 11,  and the diagnosis of dis-
seminated fusariosis was confirmed.  Because β-D glu-
can also had jumped up to 49 pg/mL,  we resumed 
CPFG even though T-Bil had already risen to 10.5 mg/
dL.  However,  the fever did not resolve.  Thus we 
replaced the central venous catheter and dwelled blood 
access for the blood purification on day 15.  On day 16,  
because congestion had progressed,  we started ventila-
tor management and continuous hemofiltration dialysis.  
Granulocytes finally appeared on day 18; however,  
β-D glucan surged to 82 pg/mL,  and Fusarium was 
repeatedly detected in the blood culture.  Although 
exacerbation of fusariosis was evident,  ferritin also 
increased to 26,039.9 pg/mL,  which led us to suspect 
hemophagocytic syndrome,  and we reluctantly admin-
istered a small amount of steroids.
However,  with the exacerbation of hemophagocytic 
syndrome,  lactate dehydrogenase increased rapidly 
afterward,  and organ function deteriorated.  The patient 
died on day 20.  We respected his family’s wishes and 
did not dissect his body.  Gene analysis performed by 
sequencing the translocation elongation factor 1α of the 
culture sample revealed that the causative agent was 
Fusarium sacchari belonging to the Fusarium fujikuroi 
species complex (SC); antifungal susceptibility for this 
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species in vitro is poor,  except for L-AMB (Table 2).
Dsicussion
Fusarium species are filamentous fungi with septa 
3-8 μm in diameter,  acute-angle branching,  and a wide 
distribution in soil and water [2].  Fusaria are subdi-
vided into approximately 200 types of species.  These 
species are roughly grouped into 10 SCs.  Of these,  
Fusarium solani SC,  Fusarium oxysporum SC,  and 
Fusarium fujikuroi SC are thought to be the most com-
mon etiologic agents of human infection [3].  In immu-
nocompetent patients,  the infections are sporadic,  
often converging with keratitis or onychomycosis [4].  In 
contrast,  immunocompromised patients,  especially 
those with long-term neutropenia,  can be infected via 
contact with contaminated water or by inhalation of 
airborne fungi,  developing disseminated disease with a 
dismal prognosis,  in some cases progressing to out-
breaks [5 , 6].  The prevalence of fusariosis is < 1% of 
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Fig. 2　 Clinical course of transplantation.
L-AMB,  liposomal amphotericin B; VRCZ,  voriconazole; CPFG,  caspofungin; β-D,  β-D-glucan;  neut,  neutrophils; CRP,  C-reactive 
protein; WBC,  white blood cell; T-Bil,  total bilirubin; TAC,  tacrolimus; Plt,  platelets;  Cre,  creatinine; LDH,  lactate dehydroge-
nase; CHDF,  continuous renal replacement therapy.
Table 2　 Minimal inhibitory concentrations of Fusarium sacchari
L-AMB FLCZ ITCZ VRCZ Posaconazole Isavuconazole MCFG CPFG 5FC MCZ
This case 1 >64 > 8 4 NA NA >16 >16 >64 4
Previous reports (5) 1.5 >64 >16 3 1.81 7.3 > 8 NA NA NA
L-AMB,  liposomal amphotericin B; FLCZ,  fluconazole; ITCZ,  itraconazole; VRCZ,  voriconazole; MCFG,  micafungin; CPFG,  caspo-
fungin; 5FC,  flucytosine; MCZ,  miconazole;  NA,  not applicable.
patients with HSCT or AML in Europe and North 
America [7],  whereas it is relatively common in South 
America,  where fusariosis accounts for 5% of deep 
mycosis in patients undergoing HSCT [8].  The etiolog-
ical species also vary widely by region.  For instance,  
Fusarium fujikuroi SC is predominant in Europe [3],  
whereas Fusarium solani SC is common in Brazil [9].
Fusarium fujikuroi SC is the pathogen that causes 
bakanae disease (blight seedling disease) in rice,  which 
is roughly classified into group G and group F.  The for-
mer produces gibberellin,  which has phytohormonal 
activity,  and the latter produces fumonisin,  a myco-
toxin [10].  Gibberellin produced by group G is thought 
to play a role in tissue infiltration [11].  In the afore-
mentioned European study,  Fusarium fujikuroi SC 
infection accounted for not only a high percentage of 
total fusariosis but also a high frequency of dissemi-
nated diseases,  as described below.  This situation could 
reflect the strength of tissue invasiveness by gibberellin.
The initial symptom of fusariosis is a fever that is 
resistant to antibacterial and antifungal therapies.  
Along with the disease progression,  sinusitis,  pneumo-
nia,  and disseminated diseases can occur.  In dissemi-
nated fusariosis,  as in this case,  numerous erythema 
and painful papules appear within a few days,  mainly in 
the extremities.  Also,  blood cultures are positive in 
approximately 40% of the cases because Fusarium can 
grow and sporulate in vivo [12].  Diagnosis is relatively 
simple in cases with positive blood cultures.  In con-
trast,  it is difficult to make a definitive diagnosis with-
out cultivations,  since disease-specific staining material 
for pathological examination is not widely available.  In 
such cases,  clinicians must start the treatment using 
clinical symptoms.  However,  not only is Fusarium 
resistant to many antifungal drugs,  but also the mini-
mal inhibitory concentrations of these drugs vary 
widely among species,  making empiric treatment diffi-
cult.  In real clinical practice,  treatments with L-AMB 
or VRCZ are often adopted [13].  Moreover,  combina-
tion therapies using multiple antifungal drugs are often 
adopted to ensure that some of the drugs would be 
effective,  including echinocandins,  which are reported 
to be ineffective in vitro [13 , 14],  because there is a 
great diversity in antifungal susceptibility for each spe-
cies as described earlier,  and the mortality rate of dis-
seminated fusariosis reaches 60-80% [15].
In this case,  Fusarium sacchari continued to be rela-
tively susceptible to L-AMB in vitro,  in line with a pre-
vious report (Table 2) [16].  Nevertheless,  it was diffi-
cult to control the infection with L-AMB alone in this 
case.  This challenge reflects the fact that the recovery of 
neutrophil counts is the most important prognostic fac-
tor in disseminated fusariosis.  Previous studies evaluat-
ing the therapeutic effects of L-AMB or VRCZ have 
reported a better prognosis for patients whose neutro-
phil counts were recovered [17 , 18].  Thus,  the treat-
ment for disseminated fusariosis requires a long period 
of time until normal hematopoiesis returns and the sign 
of infection improves.  In other words,  it is very diffi-
cult to cure disseminated fusariosis in persistent pancy-
topenia.  A new azole antifungal agent,  posaconazole,  
has been approved and reported to be effective for treat-
ing resistant/intolerable disseminated fusariosis over-
seas [19]; however,  its sensitivity to Fusarium fujikuroi 
SC is comparable with that of VRCZ [16].  It is unlikely 
that this agent would have been helpful in our case.  On 
the other hand,  VRCZ or posaconazole is thought to be 
effective for the primary prophylaxis of fusariosis [20].  
Therefore,  if we had chaged the antifungal drug to 
VRCZ earlier,  the disseminated fusariosis may not have 
occurred.
We performed allogeneic HSCT because the under-
lying disease was refractory AML,  which prevented our 
using G-CSF.  Because this patient had various organ 
dysfunctions in addition to disseminated fusariosis 
before transplantation,  the hematopoietic cell trans-
plantation-specific comorbidity index score was 4 
points and the 2-year non-relapse mortality rate was 
predicted to be approximately 40% [21].  However,  
given the high mortality rate of both refractory AML 
and disseminated fusariosis and the previous reports 
that hematopoietic stem cell transplantation cured 
refractory deep mycosis other than that by fusarium due 
to cytopenia associated with the underlying disease 
[22 , 23],  we decided to perform HSCT with informed 
consent from the patient.
The disseminated fusariosis often recurs when neu-
trophil counts decline again with chemotherapy,  even 
after the disease resolves with antifungal therapy [15].  
Only two reports described disseminated fusariosis 
before allogeneic transplantation [24 , 25],  and both 
these patient had long-term survival after transplanta-
tion.  The survival in both cases was attributed to the 
recovery of normal hematopoiesis before transplanta-
tion,  which cured the disseminated fusariosis.  To our 
knowledge,  our present report was the first to describe 
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allogeneic transplantation with active fusariosis,  but 
unfortunately we could not save the patient.  This differ-
ence may also have been related to the pathogens 
involved.  In the two studies mentioned above,  the 
pathogen was Fusarium solani SC,  while in the present 
case the pathogen was Fusarium fujikuroi SC,  which 
might be more invasive due to its production of 
Gibberellin.
One study had reported that granulocyte transfu-
sion was effective [26],  although we were unable to 
perform this procedure because we did not receive a 
review by the ethical board on time.  If we had been able 
to perform granulocyte transfusion during the trans-
plantation,  the fusariosis exacerbation before engraft-
ment might have been prevented.  Moreover,  a report 
from the Center for International Blood and Marrow 
Transplant Research showed that fungal infections 
increase non-relapse mortality in HSCT for hemato-
logic malignancies,  although this effect was smaller 
than mortality by the underlying disease,  and therefore 
the authors concluded that the presence of fungal infec-
tions is not a contraindication for HSCT [27].  Thus,  
aside from the presence of fusariosis,  the lack of control 
of the underlying disease might affect the outcome.
We chose a conditioning regimen using fludarabine/
busulfan/melphalan,  which is reported to be effective 
for relapsed and refractory myeloid malignancies [28];  
however,  the patient developed SOS after transplanta-
tion.  This result could have been due to the overlapping 
use of SOS-risk agents,  including long-term use of 
L-AMB and busulfan used in conditioning [29].  We 
also considered the use of total body irradiation (TBI) to 
avoid busulfan,  but we abandoned that idea because of 
a report of disseminated cutaneous candidiasis after TBI 
[30].  Therefore,  differentiation-inducing therapies using 
novel agents should be considered in the future,  instead 
of cytotoxic agents for patients with active hematologi-
cal malignancies and fusariosis,  as in our case.
In conclusion,  if physicians encounter patients with 
prolonged neutropenia and high fever during the treat-
ment of hematological diseases,  disseminated fusariosis 
should be suspected.  In such cases,  physicians should 
not only modify the antifungal drugs but should also 
make an effort to restore normal hematopoiesis,  
including G-CSF,  granulocyte transfusion and HSCT in 
some cases.
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